Jakmac-ER Tablet contains Tofacitinib 11 mg, a selective Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs). Tofacitinib works by modulating the JAK-STAT signaling pathway, thereby reducing inflammation and immune system overactivity associated with autoimmune conditions. Jakmac-ER is formulated as an extended-release tablet to provide sustained plasma concentrations, allowing once-daily dosing for improved patient compliance. Clinical studies have demonstrated its efficacy in reducing joint pain, swelling, and structural damage, as well as improving physical function and quality of life. Common adverse effects include upper respiratory tract infections, headache, and gastrointestinal disturbances; however, serious risks such as infections, malignancies, and thrombosis require careful monitoring. Prior to initiation, screening for latent tuberculosis and viral hepatitis is recommended. Caution is advised in patients with hepatic or renal impairment, and concomitant use with potent immunosuppressants should be avoided. Jakmac-ER should be prescribed and monitored by healthcare professionals experienced in managing autoimmune diseases to optimize therapeutic outcomes and minimize potential risks.